16 results on '"Moriggl, Richard"'
Search Results
2. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival
- Author
-
Kleinegger, Florian, Hofer, Eva, Wodlej, Christina, Golob-Schwarzl, Nicole, Birkl-Toeglhofer, Anna Maria, Stallinger, Alexander, Petzold, Johannes, Orlova, Anna, Krassnig, Stefanie, Reihs, Robert, Niedrist, Tobias, Mangge, Harald, Park, Young Nyun, Thalhammer, Michael, Aigelsreiter, Ariane, Lax, Sigurd, Garbers, Christoph, Fickert, Peter, Rose-John, Stefan, Moriggl, Richard, Rinner, Beate, and Haybaeck, Johannes
- Published
- 2019
- Full Text
- View/download PDF
3. Tumor target amplification: Implications for nano drug delivery systems
- Author
-
Seidi, Khaled, Neubauer, Heidi A., Moriggl, Richard, Jahanban-Esfahlan, Rana, and Javaheri, Tahereh
- Published
- 2018
- Full Text
- View/download PDF
4. 112: DEPLETION OF TETRAMERIC STAT5 IN MICE INCREASES INTRA-EPITHELIAL T CELL NICHE FORMAITON TO PROTECT INTESTINAL STEM CELL REGENERATION AGAINST RADIAIOTN INJURY.
- Author
-
Li, Haifeng, Liu, Ruixue, Gao, Wen, Moriggl, Richard, and Han, Xiaonan
- Published
- 2022
- Full Text
- View/download PDF
5. Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metalloproteinase Induction.
- Author
-
Tsareva, Svetlana A., Moriggl, Richard, Corvinus, Florian M., Wiederanders, Bernd, Schüt, Alexander, Kovacic, Boris, and Friedrich, Karlheinz
- Subjects
- *
COLON cancer , *CANCER cells , *CELL lines , *MESSENGER RNA , *METALLOPROTEINASES , *ENZYMES , *TUMORS , *CANCER invasiveness - Abstract
Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in colorectal carcinomas (CRCs). Here, we define the relationship between STAT3 function and the malignant properties of colon carcinoma cells. Elevated activation of STAT3 enhances invasive growth of the CRC cell lines. To address mechanisms through which STAT3 influences invasiveness, the protease mRNA expression pattern of CRC biopsies was analyzed and correlated with the STAT3 activity status. These studies revealed a striking coincidence of STAT3 activation and strong expression of matrix metalloproteinases MMP-1, -3, -7, and -9. Immunohistological examination of CRC tumor specimens showed a clear colocalization of MMP-1 and activated STAT3. Experimentally induced STAT3 activity in CRC cell lines enhanced both the level of MMP-1 mRNA and secreted MMP-1 enzymatic activity. A direct connection of STAT3 activity and transcription from the MMP-1 promoter was shown by reporter gene experiments. Moreover, high-affinity binding of STAT3 to STAT recognition elements in both the MMP-1 and MMP-3 promoter was demonstrated. Xenograft tumors arising from implantation of CRC cells into nude mice showed simultaneous appearance and colocalization of p-Y-STAT3 and MMP-1 expression. Our results link aberrant activity of STAT3 in CRC to malignant tumor progression through upregulated expression of MMPs. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
6. Stat5 tetramer formation is associated with leukemogenesis
- Author
-
Moriggl, Richard, Sexl, Veronika, Kenner, Lukas, Duntsch, Christopher, Stangl, Katharina, Gingras, Sebastien, Hoffmeyer, Angelika, Bauer, Anton, Piekorz, Roland, Wang, Demin, Bunting, Kevin D., Wagner, Erwin F., Sonneck, Karoline, Valent, Peter, Ihle, James N., and Beug, Hartmut
- Subjects
- *
TETRAMERS (Oligomers) , *LEUKEMIA , *CANCER , *BONE marrow , *IMMUNE system - Abstract
Activation of Stat5 is frequently found in leukemias. To study the mechanism and role of Stat5 activation, we introduced a constitutively activated Stat5a mutant, cS5F, into murine bone marrow (BM) cells. BM transplantation with cS5F-transfected cells caused development of multilineage leukemias in lethally irradiated wild-type or nonirradiated Rag2−/− mice. The leukemic cells showed strongly enhanced levels of cS5F tetramers but unchanged cS5F dimer levels in a DNA binding assay. Moreover, Stat5a mutants engineered to form only dimers, but not tetramers, failed to induce leukemias. In addition, Stat5 tetramers were found to accumulate in excess compared to dimers in various human leukemias. These data suggest that Stat5 tetramers are associated with leukemogenesis. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
7. STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue.
- Author
-
Kaltenecker, Doris, Spirk, Katrin, Ruge, Frank, Grebien, Florian, Herling, Marco, Rupprecht, Anne, Kenner, Lukas, Pohl, Elena E., Mueller, Kristina M., and Moriggl, Richard
- Abstract
Increasing energy expenditure through activation of brown adipose tissue (BAT) thermogenesis is an attractive approach to counteract obesity. It is therefore essential to understand the molecular mechanisms that control BAT functions. Until now several members of the Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pathway have been implicated as being relevant for BAT physiology. However, whether the STAT family member STAT5 is important for the thermogenic property of adipose tissues is unknown. Therefore, we have investigated the role of STAT5 in thermogenic fat in this paper. We performed metabolic and molecular analyses using mice that harbor an adipocyte-specific deletion of Stat5a/b alleles. We found that STAT5 is necessary for acute cold-induced temperature maintenance and the induction of lipid mobilization in BAT following β 3 -adrenergic stimulation. Moreover, mitochondrial respiration of primary differentiated brown adipocytes lacking STAT5 was diminished. Increased sensitivity to cold stress upon STAT5 deficiency was associated with reduced expression of thermogenic markers including uncoupling protein 1 (UCP1), while decreased stimulated lipolysis was linked to decreased protein kinase A (PKA) activity. Additionally, brown remodeling of white adipose tissue was diminished following chronic β 3 -adrenergic stimulation, which was accompanied by a decrease in mitochondrial performance. We conclude that STAT5 is essential for the functionality and the β-adrenergic responsiveness of thermogenic adipose tissue. • Impaired temperature maintenance in mice deficient in adipocyte STAT5 after acute cold exposure. • Blocked β 3 -adrenergic induction of lipolysis and PKA activity in BAT upon STAT5 deficiency. • Reduced respiratory capacity in primary differentiated brown adipocytes lacking STAT5. • Diminished brown remodeling of STAT5 deficient ScWAT after chronic β 3 -adrenergic stimulation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. P097 REGULATION OF PANETH CELL LINEAGES FOR REGIONAL IMMUNE SPECIALIZATION TO CONTROL COMORBIDITY OF C. DIFFICILE INFECTION WITH IBD.
- Author
-
Li, Haifeng, Liu, Ruixue, Zhang, Dongsheng, Li, Na, Cai, Juan, Moriggl, Richard, Wells, James, Denson, Lee, and Han, Xiaonan
- Published
- 2018
- Full Text
- View/download PDF
9. 32 Cytokine-STAT5 Signaling Controls Intestinal Stem Cell Activation to Suppress Clostridium Difficile - Induced Gut Inflammation.
- Author
-
Zhang, Dongsheng, Mayhew, Christopher, Gilbert, Shila, Bangar, Hansraj, Cha, Sang-wook, Watson, Carey L., Haslam, David, Helmrath, Michael, Moriggl, Richard, Denson, Lee, Wells, James, and Han, Xiaonan
- Published
- 2016
- Full Text
- View/download PDF
10. STAT1 acts as a tumor promoter for leukemia development
- Author
-
Kovacic, Boris, Stoiber, Dagmar, Moriggl, Richard, Weisz, Eva, Ott, René G., Kreibich, Rita, Levy, David E., Beug, Hartmut, Freissmuth, Michael, and Sexl, Veronika
- Subjects
- *
TUMORS , *LEUKEMIA , *MICE , *CANCER cells , *PROTEINS - Abstract
Summary: The tumor suppressor STAT1 is considered a key regulator of the surveillance of developing tumors. Here, we describe an unexpected tumor-promoting role for STAT1 in leukemia. STAT1−/− mice are partially protected from leukemia development, and STAT1−/− tumor cells induce leukemia in RAG2−/− and immunocompetent mice with increased latency. The low MHC class I protein levels of STAT1−/− tumor cells enable efficient NK cell lysis and account for the enhanced tumor clearance. Strikingly, STAT1−/− tumor cells acquire increased MHC class I expression upon leukemia progression. These findings define STAT1 as a tumor promoter in leukemia development. Furthermore, we describe the upregulation of MHC class I expression as a general mechanism that allows for the escape of hematopoietic malignancies from immune surveillance. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
11. Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth.
- Author
-
Corvinus, Florian M., Orth, Carina, Moriggl, Richard, Tsareva, Svetlana A., Wagner, Stefan, Pfitzner, Edith B., Baus, Daniela, Kaufmann, Roland, Huber, Lukas A., Zatloukal, Kurt, Beug, Hartmut, Öhlschläger, Peter, Schütz, Alexander, Halbhuber, Karl-Jürgen, and Friedrich, Karlheinz
- Subjects
- *
COLON cancer , *MORTALITY , *CELLULAR signal transduction , *CANCER cells , *LYMPHOCYTES , *CELL lines - Abstract
Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries. It has so far been molecularly defined mainly by alterations of the Wnt pathway. We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC. Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium. Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture. However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation. STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-negative variant impaired IL-6-driven proliferation. Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
12. Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
- Author
-
Tripolt, Sabrina, Neubauer, Heidi A., Knab, Vanessa M., Elmer, Dominik P., Aberger, Fritz, Moriggl, Richard, and Fux, Daniela A.
- Subjects
- *
METASTATIC breast cancer , *CANCER cell migration , *NALTREXONE , *EPITHELIAL-mesenchymal transition , *BREAST cancer prognosis , *CANCER invasiveness , *CADHERINS - Abstract
The opioid crisis of pain medication bears risks from addiction to cancer progression, but little experimental evidence exists. Expression of δ-opioid receptors (DORs) correlates with poor prognosis for breast cancer patients, but mechanistic insights into oncogenic signaling mechanisms of opioid-triggered cancer progression are lacking. We show that orthotopic transplant models using human or murine breast cancer cells displayed enhanced metastasis upon opioid-induced DOR stimulation. Interestingly, opioid-exposed breast cancer cells showed enhanced migration and strong STAT3 activation, which was efficiently blocked by a DOR-antagonist. Furthermore, opioid treatment resulted in down-regulation of E-Cadherin and increased expression of epithelial-mesenchymal transition markers. Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo. We conclude on a novel mechanism whereby opioid-triggered breast cancer metastasis occurs via oncogenic JAK1/2-STAT3 signaling to promote epithelial-mesenchymal transition. These findings emphasize the importance of selective and restricted opioid use, as well as the need for safer pain medication that does not activate these oncogenic pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
- Author
-
Merkel, Olaf, Taylor, Ninon, Prutsch, Nicole, Staber, Philipp B., Moriggl, Richard, Turner, Suzanne D., and Kenner, Lukas
- Subjects
- *
P53 antioncogene , *TUMOR growth , *GENE therapy , *GENETIC mutation , *CANCER treatment - Abstract
The p53 tumor suppressor is inactivated in most cancers, thus suggesting that loss of p53 is a prerequisite for tumor growth. Therefore, its reintroduction through different means bears great clinical potential. After a brief introduction to current knowledge of p53 and its regulation by the ubiquitin-ligases MDM2/MDMX and post-translational modifications, we will discuss small molecules that are able to reactivate specific, frequently observed mutant forms of p53 and their applicability for clinical purposes. Many malignancies display amplification of MDM genes encoding negative regulators of p53 and therefore much effort to date has concentrated on the development of molecules that inhibit MDM2, the most advanced of which are being tested in clinical trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma. These will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4 . Finally, we will also touch on gene therapy and vaccination approaches; the former of which aims to replace mutated TP53 and the latter whose goal is to activate the body’s immune system toward mutant p53 expressing cells. Besides the obvious importance of MDM2 and MDMX expression for regulation of p53, other regulatory factors should not be underestimated and are also described. Despite the beauty of the concept, the past years have shown that many obstacles have to be overcome to bring p53 reactivation to the clinic on a broad scale, and it is likely that in most cases it will be part of a combined therapeutic approach. However, improving current p53 targeted molecules and finding the best therapy partners will clearly impact the future of cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Structural and mutational analysis of member-specific STAT functions.
- Author
-
Erdogan, Fettah, Qadree, Abdul K., Radu, Tudor B., Orlova, Anna, de Araujo, Elvin D., Israelian, Johan, Valent, Peter, Mustjoki, Satu M., Herling, Marco, Moriggl, Richard, and Gunning, Patrick T.
- Subjects
- *
STAT proteins , *GENE expression , *TARGETED drug delivery , *COMMUNICABLE diseases - Abstract
The STAT family of transcription factors control gene expression in response to signals from various stimulus. They display functions in diseases ranging from autoimmunity and chronic inflammatory disease to cancer and infectious disease. This work uses an approach informed by structural data to explore how domain-specific structural variations, post-translational modifications, and the cancer genome mutational landscape dictate STAT member-specific activities. We illustrated the structure-function relationship of STAT proteins and highlighted their effect on member-specific activity. We correlated disease-linked STAT mutations to the structure and cancer genome mutational landscape and proposed rational drug targeting approaches of oncogenic STAT pathway addiction. Hyper-activated STATs and their variants are associated with multiple diseases and are considered high value oncology targets. A full understanding of the molecular basis of member-specific STAT-mediated signaling and the strategies to selectively target them requires examination of the difference in their structures and sequences. • Hyper-activated STATs are a high value oncology pharmacologic target. • Domain-specific variations dictate STAT member-specific activities. • STAT structural data illuminates mechanism of disease-linked STAT mutations. • Member-specific STAT activity is guided by post-translational modifications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development
- Author
-
Mueller, Kristina M., Themanns, Madeleine, Friedbichler, Katrin, Kornfeld, Jan-Wilhelm, Esterbauer, Harald, Tuckermann, Jan P., and Moriggl, Richard
- Subjects
- *
GLUCOCORTICOID receptors , *SOMATOTROPIN , *CELLULAR signal transduction , *LIVER cancer , *FATTY degeneration , *HOMEOSTASIS , *METABOLIC disorders - Abstract
Abstract: Growth hormone (GH) and glucocorticoids (GCs) are involved in the control of processes that are essential for the maintenance of vital body functions including energy supply and growth control. GH and GCs have been well characterized to regulate systemic energy homeostasis, particular during certain conditions of physical stress. However, dysfunctional signaling in both pathways is linked to various metabolic disorders associated with aberrant carbohydrate and lipid metabolism. In liver, GH-dependent activation of the transcription factor signal transducer and activator of transcription (STAT) 5 controls a variety of physiologic functions within hepatocytes. Similarly, GCs, through activation of the glucocorticoid receptor (GR), influence many important liver functions such as gluconeogenesis. Studies in hepatic Stat5 or GR knockout mice have revealed that they similarly control liver function on their target gene level and indeed, the GR functions often as a cofactor of STAT5 for GH-induced genes. Gene sets, which require physical STAT5–GR interaction, include those controlling body growth and maturation. More recently, it has become evident that impairment of GH-STAT5 signaling in different experimental models correlates with metabolic liver disease, ranging from hepatic steatosis to hepatocellular carcinoma (HCC). While GH-activated STAT5 has a protective role in chronic liver disease, experimental disruption of GC-GR signaling rather seems to ameliorate metabolic disorders under metabolic challenge. In this review, we focus on the current knowledge about hepatic GH-STAT5 and GC-GR signaling in body growth, metabolism, and protection from fatty liver disease and HCC development. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output
- Author
-
Li, Geqiang, Wang, Zhengqi, Zhang, Yi, Kang, Zizhen, Haviernikova, Eleonora, Cui, Yongzhi, Hennighausen, Lothar, Moriggl, Richard, Wang, Demin, Tse, William, and Bunting, Kevin D.
- Subjects
- *
BLOOD cells , *BONE marrow cells , *HEMATOPOIETIC stem cells , *BILIARY tract - Abstract
Objective: Signal transducer and activator of transcription 5 (STAT5) is a critical regulator of hematopoietic development and its impaired activation is associated with hematopoietic and immune cell defects. However, much of this information has been learned from knockout mice that still retain the potential for expression of STAT5 proteins that are N-terminally truncated due to alternative internal translation initiation codons. The goal of these studies was to use transplantation-based assays to analyze the degree of STAT5ΔN activity in hematopoietic stem cells (HSC) and throughout lymphomyeloid development. Methods: We have directly compared E14.5 fetal liver cells from mice with potential to express STAT5abΔN (STAT5abΔN/ΔN) with mice completely lacking STAT5a and STAT5b (STAT5abnull/null). We have also utilized retroviral complementation of STAT5abnull/null fetal liver HSC to enforce expression of full-length STAT5a or STAT5a lacking the first 136 amino acids (STAT5aΔN). Results: We report that STAT5 is required for HSC, lymphocyte, and erythrocyte development. We demonstrate that restored expression of STAT5a in STAT5abnull/null HSC provides a strong selective advantage, correcting T- and B-lymphocyte and erythrocyte development. Interestingly, Gr-1+ blood cells were inversely correlated with B lymphocytes and both were normalized by STAT5a expression. In contrast, transduction of STAT5aΔN only provided partial B-lymphocyte development. Conclusions: These studies define the role of STAT5 in maintaining normal lymphoid vs myeloid balance during hematopoiesis and highlight a major role for the N-domain in HSC function. The platform of retroviral complementation described here will be particularly useful for future studies to subdefine the N-domain regions that are critical for hematopoiesis. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.